Intelecta

Levocarnitine, the active ingredient in Intelecta, is a Carnitine supplement presented as an intravenous solution for intravenous use. It is employed to address primary and secondary carnitine deficiency, and is indicated for patients undergoing renal dialysis or those with inherited metabolic conditions that require carnitine supplementation.

GNH USA supplies Intelecta as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology units, pharmacies and clinics worldwide, with full regulatory documentation and cold‑chain logistics where required throughout.

Intelecta (levocarnitine) is used to correct carnitine deficits and support fatty‑acid metabolism in several clinical contexts. Carnitine deficiency: restores normal carnitine levels and improves energy metabolism. Secondary carnitine deficiency (e.g., renal dialysis): compensates for losses during dialysis and maintains metabolic function. Metabolic disorders requiring carnitine supplementation: supports patients with inherited or acquired conditions where carnitine is essential for mitochondrial fatty‑acid oxidation.

Intravenous levocarnitine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: mild discomfort or tenderness at the infusion site. - Nausea: transient feeling of queasiness during or after infusion. - Vomiting: occasional episodes following administration. - Headache: mild to moderate intensity, often resolving without intervention.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical intervention. - Arrhythmia: abnormal heart rhythm that can be life‑threatening. - Seizure: rare neurologic event occurring during or after infusion. - Severe hypotension: profound drop in blood pressure leading to dizziness or syncope.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for potential complications. - Assess carnitine levels: confirm deficiency prior to treatment. - Monitor cardiac function: watch for arrhythmias during infusion. - Check renal function: adjust therapy in patients with severe renal impairment. - Avoid rapid infusion: administer over the recommended period to reduce hypotension risk. - Observe for allergic reactions: discontinue if severe hypersensitivity occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levocarnitine may interact with other medications, influencing efficacy or safety.

Major Interactions (Avoid): - Concomitant use with valproic acid: may increase risk of hyperammonemia. - Concurrent high‑dose insulin: can potentiate hypoglycemia.

Moderate Interactions (Monitor Closely): - Loop diuretics: may increase renal loss of carnitine, reducing effectiveness. - Anticoagulants (e.g., warfarin): may alter INR values, requiring closer monitoring. - Phenobarbital: may enhance hepatic metabolism of levocarnitine, potentially lowering plasma concentrations.